Generic Upneeq Availability
Last updated on Jul 9, 2025.
Upneeq is a brand name of oxymetazoline ophthalmic, approved by the FDA in the following formulation(s):
UPNEEQ (oxymetazoline hydrochloride - solution/drops;ophthalmic)
-
Manufacturer: RVL PHARMS
Approval date: July 8, 2020
Strength(s): 0.1% [RLD]
Is there a generic version of Upneeq available?
No. There is currently no therapeutically equivalent version of Upneeq available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Upneeq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for treating ocular disorders
Patent 10,799,481
Issued: October 13, 2020
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL PHARMACEUTICALS, INC.The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Oxymetazoline compositions
Patent 10,814,001
Issued: October 27, 2020
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Oxymetazoline compositions
Patent 10,898,573
Issued: January 26, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Compositions and methods for non-surgical treatment of ptosis
Patent 10,912,765
Issued: February 9, 2021
Inventor(s): Silverberg Mark
Assignee(s): VOOM, LLCProvided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031✓
- August 26, 2031
-
Compositions and methods for treating ocular disorders
Patent 10,940,138
Issued: March 9, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Oxymetazoline compositions
Patent 11,103,482
Issued: August 31, 2021
Inventor(s): deVries Tina & Jacobs David
Assignee(s): RVL Pharmaceuticals, Inc.The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Oxymetazoline compositions
Patent 11,311,515
Issued: April 26, 2022
Inventor(s): Devries; Tina et al.
Assignee(s): RVL Pharmaceuticals, Inc. (Bridgewater, NJ)The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Compositions and methods for treating ocular disorders
Patent 11,324,722
Issued: May 10, 2022
Inventor(s): deVries; Tina et al.
Assignee(s): RVL Pharmaceuticals, Inc. (Bridgewater, NJ)The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Oxymetazoline compositions
Patent 11,541,036
Issued: January 3, 2023
Inventor(s): Devries; Tina et al.
Assignee(s): RVL PHARMACEUTICALS, INC. (Bridgewater, NJ)The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Compositions and methods for treating ocular disorders
Patent 11,701,343
Issued: July 18, 2023
Inventor(s): deVries; Tina et al.
Assignee(s): RVL Pharmaceuticals, Inc. (Bridgewater, NJ)The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Patent expiration dates:
- December 16, 2039✓
- December 16, 2039
-
Compositions and methods for non-surgical treatment of ptosis
Patent 8,357,714
Issued: January 22, 2013
Inventor(s): Silverberg Mark
Assignee(s): Voom, LLCProvided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031✓
- August 26, 2031
-
Compositions and methods for non-surgical treatment of Ptosis
Patent 9,867,808
Issued: January 16, 2018
Inventor(s): Silverberg Mark
Assignee(s): VOOM, LLCProvided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Patent expiration dates:
- August 26, 2031✓
- August 26, 2031
More about Upneeq (oxymetazoline ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (18)
- Drug images
- Side effects
- Dosage information
- FDA approval history
- Breastfeeding
- En español
Patient resources
Other brands
OcuClear, Visine L.R. Long Lasting Redness Relief
Professional resources
Other brands
Visine L.R. Long Lasting Redness Relief
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
